Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

Figure 2

Costs per cycle: All-cause and neutropenia-related. Healthcare resource costs, for cycles in which pegfilgrastim and filgrastim were used prophylactically, were calculated on a per-cycle basis to provide total costs as well as subgroup costs by setting of care: ambulatory care, emergency room, and hospitalizations. The costs were direct costs for services covered under patients’ insurance benefits and represented the reimbursed amount paid by the patient and insurer.

Back to article page